GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Otonomy Inc (OTCPK:OTIC) » Definitions » Receivables Turnover

Otonomy (Otonomy) Receivables Turnover : 0.00 (As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Otonomy Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Otonomy's Revenue for the three months ended in Sep. 2022 was $0.00 Mil. Otonomy's average Accounts Receivable for the three months ended in Sep. 2022 was $0.00 Mil.


Otonomy Receivables Turnover Historical Data

The historical data trend for Otonomy's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Otonomy Receivables Turnover Chart

Otonomy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.48 6.93 5.56 - -

Otonomy Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Otonomy's Receivables Turnover

For the Biotechnology subindustry, Otonomy's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Otonomy's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Otonomy's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Otonomy's Receivables Turnover falls into.



Otonomy Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Otonomy's Receivables Turnover for the fiscal year that ended in Dec. 2021 is calculated as

Receivables Turnover (A: Dec. 2021 )
=Revenue / Average Total Inventories
=Revenue (A: Dec. 2021 ) / ((Accounts Receivable (A: Dec. 2020 ) + Accounts Receivable (A: Dec. 2021 )) / count )
=0.125 / ((0 + 0) / 1 )
=0.125 / 0
=N/A

Otonomy's Receivables Turnover for the quarter that ended in Sep. 2022 is calculated as

Receivables Turnover (Q: Sep. 2022 )
=Revenue / Average Total Inventories
=Revenue (Q: Sep. 2022 ) / ((Accounts Receivable (Q: Jun. 2022 ) + Accounts Receivable (Q: Sep. 2022 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Otonomy  (OTCPK:OTIC) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


Otonomy Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Otonomy's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Otonomy (Otonomy) Business Description

Traded in Other Exchanges
N/A
Address
4796 Executive Drive, San Diego, CA, USA, 92121
Otonomy Inc is a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation for the treatment of tinnitus. All the business activity primarily operates through the region of the United States.
Executives
Hogan H Michael Iii director C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Alan Charles Foster officer: Chief Scientific Officer 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Savel Robert Michael Ii officer: Chief Technical Officer 1025 OPAL WAY, VACAVILLE CA 95687
Paul E Cayer officer: CFO/Ch. Business Offcr & Sec. C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
David Allen Weber director, officer: President & CEO C/O OTONOMY, INC., 6275 NANCY RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
Jill Marie Broadfoot director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Ciara Kennedy director C/O LUMENA PHARMACEUTICALS, INC., 12531 HIGH BLUFF DRIVE, SUITE 110, SAN DIEGO CA 92130
James B Breitmeyer director
Eric J Loumeau officer: GC & Chief Compliance Officer C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Katherine Mary Bishop officer: Chief Scientific Officer C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO CA 92121
Carl Lebel officer: Chief Scientific Officer 23256 MARIPOSA DE ORO, MALIBU CA 90265
Iain Mcgill director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Chau Quang Khuong director C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022